Lartesertib

Lartesertib (M4076) is an inhibitor of the serine/threonine protein kinase ATM with high potency. Lartesertib can inhibit the growth of multiple hematopoietic cell lines. Additionally, when combined with the ATR inhibitor Tuvusertib (HY-111451), Lartesertib can promote the death of tumor cells, activate the immune signaling pathway, and exhibit anti-tumor activity[1][2].

Product Specifications

CAS Number

[2495096-26-7]

Product Name Alternative

M4076; ATM Inhibitor-5

UNSPSC

12352005

Target

ATM/ATR; PD-1/PD-L1; STING

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Immunology/Inflammation; PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/atm-inhibitor-5.html

Purity

99.94

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(N1C2=C(F)C=NC=C2OC)N(C)C3=C1C4=CC(C5=CN(C)N=C5C)=C(OC)C=C4N=C3

Molecular Formula

C23H21FN6O3

Molecular Weight

448.45

References & Citations

[1]Mukker J K, et al. In vitro evaluation of myelosuppressive effects of ATRi tuvusertib and ATMi lartesertib (M4076), alone and in combination. Cancer Research, 2024, 84 (6_Supplement) : 7186-7186.|[2]Laaber K, et al. Combined inhibition of ATR and ATM with tuvusertib and lartesertib (M4076) impacts the tumor microenvironment. Cancer Research, 2024, 84 (6_Supplement) : 5617-5617.